Department of Medical Oncology, National Institute of Neoplastic Diseases, Lima, Peru.
Department of Medical Oncology, Gustave Roussy, Paris Saclay University, Villejuif, France.
Cancer Treat Rev. 2024 Sep;129:102801. doi: 10.1016/j.ctrv.2024.102801. Epub 2024 Jul 17.
Renal cell carcinoma (RCC) is a heterogenous disease which the incidence is increasing worldwide. The identification and understanding of the role of the Von Hipple Lindau (VHP) in regulating the hypoxia-inducible factor signaling pathway has revolutionized the treatment of this disease. Belzutifan is an oral hypoxia-inducible factor (HIF)-2α inhibitor, which has demonstrated efficacy in treating von Hippel-Lindau (VHL) disease and for the treatment of adults with RCC who experienced disease progression after PD-1/PD-L1- and VEGFR-targeted therapies. One of the most common adverse effect of this drug is anemia; however, it is treatment is not well known. This review summarizes role of the VHL-HIF pathway in ccRCC aroused the interest of targeting HIF activity, the history of belzutifan development and their relationship to anemia as well as propose a management algorithm.
肾细胞癌 (RCC) 是一种异质性疾病，其发病率在全球范围内呈上升趋势。阐明并了解 Von Hipple Lindau (VHP) 在调节低氧诱导因子信号通路中的作用，彻底改变了这种疾病的治疗方法。贝伐珠单抗是一种口服低氧诱导因子 (HIF)-2α 抑制剂，已被证明可有效治疗 von Hippel-Lindau (VHL) 疾病，并可用于治疗接受 PD-1/PD-L1 和 VEGFR 靶向治疗后疾病进展的成人 RCC 患者。该药最常见的不良反应之一是贫血；然而，其治疗方法并不为人所知。本文综述了 VHL-HIF 通路在 ccRCC 中的作用引起了人们对靶向 HIF 活性的兴趣，介绍了贝伐珠单抗的发展历程及其与贫血的关系，并提出了管理算法。
